Local Institution - 0011
Hořovice, Beroun, Czechia
12 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bipolar DisorderMania
Bristol-Myers Squibb424 enrolled103 locationsNCT07140913
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 1
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer
Bristol-Myers Squibb234 enrolled21 locationsNCT06997029
Recruiting
Phase 2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled93 locationsNCT07015983
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb596 enrolled186 locationsNCT07100080
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb129 enrolled46 locationsNCT07291076
Recruiting
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
Hypertrophic Cardiomyopathy
Bristol-Myers Squibb500 enrolled15 locationsNCT07361289
Recruiting
Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Alzheimer DiseaseAgitation
Celgene120 enrolled52 locationsNCT06808984
Recruiting
Phase 2Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Bristol-Myers Squibb590 enrolled264 locationsNCT07063745
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb690 enrolled160 locationsNCT07221149
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity
Celgene200 enrolled53 locationsNCT06782490
Recruiting
Phase 2
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
Anemia
Bristol-Myers Squibb189 enrolled36 locationsNCT05664737
Recruiting
Phase 1Phase 2
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb240 enrolled11 locationsNCT07325136
Recruiting
Phase 4
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb50 enrolled31 locationsNCT07004972
Recruiting
Phase 3
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Renal Allograft Recipients
Bristol-Myers Squibb102 enrolled38 locationsNCT04877288
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled279 locationsNCT06764485
Recruiting
Phase 2
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure
Bristol-Myers Squibb208 enrolled117 locationsNCT06122779
Recruiting
Phase 3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Bristol-Myers Squibb153 enrolled63 locationsNCT04772079